Amendments to the Claims

Please cancel Claims 39-43, 54-58 and 68-86. Please amend Claims 36, 37, 52 and 53. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-35. Canceled.

36. (Currently amended) A composition comprising a portion of a heat shock protein (hsp), wherein: the portion of the hsp is joined to a heterologous protein; the portion of the hsp is limited to SEQ ID NO:8 ~~or a homolog thereof~~; and the composition, when administered to an animal in a physiologically acceptable formulation, elicits a $CD8^+$ cytotoxic T lymphocyte (CTL) response that is greater than the response elicited by administration of the heterologous protein alone.

37. (Currently amended) The composition of claim 36, wherein the portion of the hsp~~, or the homolog thereof,~~ is joined to the heterologous protein by a covalent bond.

38. (Previously presented) The composition of claim 37, wherein the covalent bond is a peptide bond.

39-43. Canceled.

44. (Previously presented) The composition of claim 36, wherein the heterologous protein is a viral antigen.

45. (Previously presented) The composition of claim 44, wherein the viral antigen is an antigen of an influenza virus, a human papilloma virus (HPV), a herpes virus, or a human immunodeficiency virus (HIV).

46. (Previously presented) The composition of claim 45, wherein the HIV antigen is p24 or gp41, the influenza virus antigen is nucleoprotein, or the HPV antigen is E7.

47. (Previously presented) The composition of claim 36, wherein the heterologous protein is glycosylated.

48. (Previously presented) The composition of claim 36, wherein the heterologous protein is a toxin.

49. (Previously presented) The composition of claim 36, wherein the heterologous protein is an antigen of a bacterial cell or a mycobacterial cell.

50. (Previously presented) The composition of claim 36, wherein the composition is formulated as a physiologically acceptable composition.

51. (Previously presented) The composition of claim 50, further comprising an adjuvant, a pharmaceutically acceptable surfactant, an excipient, a carrier, or a diluent.

52. (Currently amended) The composition of claim ~~50~~ 36, wherein the ~~fusion protein~~ composition is associated with a liposome.

53. (Currently amended) A composition comprising a fusion protein consisting of a portion of a heat shock protein (hsp) and a heterologous protein, wherein the portion of the hsp is limited to SEQ ID NO:8 ~~or a homolog thereof~~ and the composition, when administered to an animal in a physiologically acceptable formulation, elicits a $CD8^+$ cytotoxic T lymphocyte (CTL) response that is greater than the response elicited by administration of the heterologous protein alone.

54-58. Canceled.

59. (Previously presented) The composition of claim 53, wherein the heterologous protein is a viral antigen.

60. (Previously presented) The composition of claim 59, wherein the viral antigen is an antigen of an influenza virus, a human papilloma virus (HPV), a herpes virus, or a human immunodeficiency virus (HIV).

61. (Previously presented) The composition of claim 60, wherein the HIV antigen is p24 or gp41, the influenza virus antigen is nucleoprotein, or the HPV antigen is E7.

62. (Previously presented) The composition of claim 53, wherein the heterologous protein is glycosylated.

63. (Previously presented) The composition of claim 53, wherein the heterologous protein is a toxin.

64. (Previously presented) The composition of claim 53, wherein the heterologous protein is an antigen of a bacterial cell or a mycobacterial cell.

65. (Previously presented) The composition of claim 53, wherein the composition is formulated as a physiologically acceptable composition.

66. (Previously presented) The composition of claim 65, further comprising an adjuvant, a pharmaceutically acceptable surfactant, an excipient, a carrier, or a diluent.

67. (Previously presented) The composition of claim 53, wherein the fusion protein is associated with a liposome.

68-86. Canceled.